(Atorvastatin + fluconazole + minocycline) is under clinical development by GlobeStar Therapeutics and currently in Phase I for Relapsing Multiple Sclerosis (RMS). According to GlobalData, Phase I drugs for Relapsing Multiple Sclerosis (RMS) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Atorvastatin + fluconazole + minocycline)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Atorvastatin + fluconazole + minocycline) overview

A fixed-dose combination of atorvastatin, fluconazole, minocycline is under development for the treatment of multiple sclerosis autoimmune diseases disseminated or multiple sclerosis Nos multiple sclerosis, acute relapsing multiple sclerosis, primary progressive multiple sclerosis, autoimmune multiple sclerosis relapsing inflammation chronic disease demyelinating disease progressive remitting relapsing. It is administered through oral route. Atorvastatin acts by targeting HMG-CoA reductase enzyme. Fluconazole acts by targeting lanosterol 14 alpha demethylase. Minocycline acts by targeting 30S ribosomal subunit.

GlobeStar Therapeutics overview

GlobeStar Therapeutics is engaged in the development and sale of Liprostin, a peripheral artery disease (PAD) therapy for controlled drug disease for its patients. It also owns patents of OmniCath I and OmniCath II atherectomy catheters. GlobeStar Therapeutics is headquartered in Richland, Washington, the US.

For a complete picture of (Atorvastatin + fluconazole + minocycline)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.